Trial Backs Shatavari and Ashwagandha Synergies in Female Sexual Wellness
Standardised Shatavari extract SRI-81 improved female sexual function scores across an eight-week trial, with enhanced additive outcomes observed when paired with KSM-66 Ashwagandha.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 26 October 2026
A randomised, double-blind, placebo-controlled clinical trial involving 135 women has demonstrated that daily oral supplementation with standardised Shatavari root extract (SRI-81) over eight weeks significantly improves Female Sexual Function Index (FSFI) scores while reducing self-reported sexual distress. Crucially for manufacturing quality controls and brand safety dossiers, investigators recorded zero serious adverse events during the eight-week intervention window, confirming the raw material's tolerability profile.
The study assessed standalone SRI-81 against a dual-active protocol combining the extract with branded KSM-66 Ashwagandha root extract. Co-administration generated an additive biological effect, producing superior improvements across composite FSFI scores compared to single-ingredient cohorts. Although Ayurvedic medicine has utilised Shatavari (Asparagus racemosus) for female reproductive health for centuries, modern functional finished goods require standardised active markers. The inclusion of KSM-66 indicates clear compounding value, enabling brands to build synergistic formulas targeting stress reduction and physical vitality simultaneously.
For contract development and manufacturing organisations (CDMOs), these findings unlock distinct opportunities in the underserved female sexual wellness segment. Formulating with validated extracts avoids the margin compression typical of commoditised botanical powders, while supporting minimum order quantities (MOQs) with defensible clinical substantiation. However, researchers cautioned that larger cohorts and extended trial durations remain necessary to determine multi-cycle efficacy and optimal dosage titration across diverse demographics.
What this means for the United Kingdom
UK brand owners targeting retail placement in Boots, Superdrug, and Holland & Barrett can deploy this botanical pairing to challenge legacy hormone-support products. Regulatory affairs teams must carefully calibrate marketing narratives to remain compliant under the Great Britain Nutrition and Health Claims register, steering clear of medicinal claims under the enforcement purview of the Medicines and Healthcare products Regulatory Agency (MHRA). Brand procurement teams should secure qualified supplier agreements for SRI-81 and KSM-66 now, preventing lead-time delays and raw material price volatility as contract manufacturers standardise these actives into next-generation women's health stock-keeping units (SKUs).
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.
This article does not constitute medical advice.